Examkin

Question

Difficulty: MediumRheumatology and Immunology

A female university student in her early 2020 s is evaluated in the rheumatology clinic for a 66-week history of profound fatigue and stiffness in her proximal interphalangeal joints. She notes that the skin across her cheeks becomes persistently red and painful after brief sun exposure. Over the past 1414 days, she has developed noticeable bilateral ankle swelling. Her blood pressure is 145/92145/92 mmHg. Laboratory evaluation shows a serum creatinine of 1.41.4 mg/dL, and urinalysis demonstrates 3+3+ proteinuria with red blood cell casts. Arrange the following clinical interventions in the standard chronological sequence for the definitive diagnostic workup and targeted management of this patient's underlying condition.

  1. 1Perform initial serologic screening with an antinuclear antibody (ANA) assay
  2. 2Obtain confirmatory serology including anti-dsDNA antibodies and complement levels
  3. 3Perform a percutaneous renal biopsy for histologic classification
  4. 4Initiate targeted induction immunosuppressive therapy (e.g., mycophenolate mofetil)

Answer

The correct chronological sequence is: 1) ANA screening, 2) Confirmatory anti-dsDNA/complement testing, 3) Percutaneous renal biopsy, 4) Targeted induction immunosuppressive therapy.
The evaluation of suspected Systemic Lupus Erythematosus (SLE) follows a strict sequence beginning with highly sensitive screening (ANA). If this is positive, highly specific markers (anti-dsDNA, anti-Smith) are evaluated to confirm the diagnosis. Because this patient exhibits clear signs of renal involvement (edema, proteinuria, RBC casts, elevated creatinine), a renal biopsy is the absolute critical next step to classify the lupus nephritis. Only after the histologic class is definitively established can the appropriate, targeted induction immunosuppressive therapy be safely initiated.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The combination of inflammatory arthritis, photosensitive malar rash, and new-onset nephropathy (hypertension, edema, proteinuria, RBC casts) is highly suspicious for Systemic Lupus Erythematosus (SLE) with lupus nephritis.
Recognizing the syndrome dictates the necessary systemic workup.
2
Determine the optimal first diagnostic test.
Antinuclear antibody (ANA) assay is ordered first.
ANA is the most sensitive screening test for SLE and is universally the first step in the serologic evaluation of suspected connective tissue diseases.
3
Determine the subsequent confirmatory test.
Anti-dsDNA, anti-Smith, and complement levels (C3, C4) are measured.
Because ANA is sensitive but not specific, these highly specific markers confirm the diagnosis of SLE and establish baseline disease activity.
4
Address the end-organ involvement.
A percutaneous renal biopsy is performed.
Clinical and laboratory evidence of nephritis requires histologic classification (Classes I-VI) because treatment pathways diverge significantly based on the tissue pathology.
5
Determine the final management step.
Targeted induction immunosuppression is initiated.
Aggressive regimens (e.g., cyclophosphamide, mycophenolate) carry significant toxicity and are specifically indicated for proliferative forms of lupus nephritis (Class III and IV) as proven by biopsy.

Key Concept

Sequential evaluation and management of suspected Systemic Lupus Erythematosus and lupus nephritis
Estimated Time:1m 0s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic